Akebia Therapeutics (AKBA) Long-Term Deferred Tax (2017 - 2019)

Akebia Therapeutics (AKBA) has 3 years of Long-Term Deferred Tax data on file, last reported at $109.4 million in Q4 2019.

• On a quarterly basis, Long-Term Deferred Tax fell 3.04% year-over-year to $109.4 million in Q4 2019; TTM through Dec 2019 was $109.4 million, a 3.04% decrease from a year earlier, with the FY2019 full-year figure at $109.4 million, down 3.04% from the prior year.
• Long-Term Deferred Tax for Q4 2019 stood at $109.4 million, down from $112.8 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for AKBA reached as high as $112.8 million in Q4 2018 and fell as low as $400000.0 in Q1 2017.
• Historically, Long-Term Deferred Tax has averaged $74.2 million across 3 years, with a median of $109.4 million in 2019.
• On a YoY basis, Long-Term Deferred Tax climbed as much as 3.04% in 2019 and fell as far as 3.04% in 2019.
• Year by year, Long-Term Deferred Tax stood at $400000.0 in 2017, then jumped by 28094.25% to $112.8 million in 2018, then slipped by 3.04% to $109.4 million in 2019.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $109.4 million in Q4 2019, $112.8 million in Q4 2018, and $400000.0 in Q1 2017.